Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
NASDAQ:INO
Inovio Pharmaceuticals (INO) Stock Price & Analysis
5,668 Followers
INO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.90 - $14.75
Previous Close$8.93
Volume333.53K
Average Volume (3M)365.61K
Market Cap
$231.38M
Enterprise Value$139.19M
Total Cash (Recent Filing)$105.61M
Total Debt (Recent Filing)$13.43M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Aug 07, 2024EPS Estimate
-$1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.53
Shares Outstanding25,910,701
10 Day Avg. Volume253,105
30 Day Avg. Volume365,610
Standard Deviation0.28
R-Squared0.03
Alpha0.00486
Financial Highlights & Ratios
Price to Book (P/B)2.22
Price to Sales (P/S)2042.06
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue194.10
Enterprise Value/Gross Profit167.30
Enterprise Value/Ebitda-1.58
Forecast
1Y Price Target
$21.00Price Target Upside135.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Inovio Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Commercialization ProspectsCommercial preparations for INO-3107 are ongoing, with a planned U.S. launch in 2025, indicating forward momentum in product commercialization.
Financial StabilityCash position estimated to potentially fund operations into 3Q25, which may support the company's financial stability in the short term.
Product PipelineINO-3107 confirmatory trial has alignment from the FDA on its design, increasing the likelihood of a successful trial outcome and approval.
Bears Say
Annual Financial PerformanceFor full-year 2023, the company reported a significant net loss of $135.1M.
Earnings MissNet loss totaled $30.5M in 1Q24, higher than the estimated loss of $27.0M.
Quarterly LossesNet loss totaled $25.0M in 4Q23 while generating minimal revenue.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $3.90 and its highest was $14.75 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Currently, no data Available
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Aug 07, 2024 which is in 32 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on May 13, 2024. The company reported -$1.31 earnings per share for the quarter, missing the consensus estimate of -$1.013 by -$0.297.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -$1.1.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 25,910,702 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$1.31 in its last earnings report, missing expectations of -$1.013. Following the earnings report the stock price went up 0.528%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Among the largest hedge funds holding Inovio Pharmaceuticals’s share is GMT Capital Corp. It holds Inovio Pharmaceuticals’s shares valued at N/A.
---
Inovio Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (135.16% Upside)
$21.00 (135.16% Upside)
Blogger Sentiment
Bullish
INO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 126.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.43%
12-Months-Change
Fundamentals
Return on Equity
-85.09%
Trailing 12-Months
Asset Growth
-51.57%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Its drug candidates include SynCon immunotherapies which helps break the immune system's tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
---
INO Earnings Call
Q1 2024
0:00 / 0:00
---
INO Stock 12 Month Forecast
Average Price Target
$21.00
▲(135.16% Upside)
Technical Analysis
Best Analysts Covering INO
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-51.90%
reiterated a buy rating 2 months ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -51.90% per trade.
---